Search Results

Home → Flash News → This study adds a key piece to the puzzle of adhesion GPCR signaling. Understanding receptor-specific nuances, like the role of NTF cleavage, is crucial for decoding their functional outcomes. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️https://www.ecosystem.drgpcr.com/adhesion-gpcrs/n-terminal-fragment-shedding-contributes-to-signaling-of-the-full-length-adhesion-receptor-adgrl3 #gpcr #drgpcr Published on January 28, 2025 Category GPCR Weekly News This study adds a key piece to the puzzle of adhesion GPCR signaling. Understanding receptor-specific nuances, like the role of NTF cleavage, is crucial for decoding their functional outcomes. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️ https:// www.ecosystem.drgpcr.com/adhesion-gpcrs/n-terminal-fragment-shedding-contributes-to-signaling-of-the-full-length-adhesion-receptor-adgrl3 #gpcr #drgpcr Previous Next Recent Articles

Turn GPCR discovery chaos into clarity—Yamina’s Corner offers expert GPCR strategy, CRO guidance, and tailored scientific support to accelerate your pipeline. Home About News Get in Touch Welcome Turn GPCR Chaos Into Insights Expert strategic and scientific consultancy to accelerate your pipeline Book My Consultation Critical Bottlenecks in Your GPCR Pipeline ❌ Overwhelming pharmacology Data ❌ Suboptimal CRO Partnerships ❌ Stalled Pipeline Progression ❌ Uncertainty in GPCR Investments Advisory Focus Areas Expert support for Biotech innovators, VC investors and CRO partners Biotech Pipeline Acceleration For Biotech Leaders & Scientists Actionable Data Insights: Translate complex GPCR pharmacology into clear decisions for lead optimization and candidate selection. Accelerated Program Progression: Design robust assay cascades and establish key go/no-go points to speed up your pipeline. Optimized CRO Collaboration: Streamline internal R&D and external CRO workflows to prevent delays and ensure preclinical success. Fuel Discovery VC Due Diligence & De-risking For Venture Capital Firms De-risk GPCR Investments: Identify critical scientific red flags and technical gaps in GPCR assets before committing capital. Actionable Scientific Validation: Ensure target companies execute the right GPCR pharmacology experiments to generate robust, decision-making data. Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic potential to inform investment strategy. Fast-Track Discovery CRO Partnership & Optimization For Contract Research Organizations Elevate Scientific Offerings: Refine and optimize your GPCR assay platforms and in vitro models to deliver superior data quality and results. Enhance Client Project Delivery: Streamline workflows and improve scientific execution to increase client satisfaction and secure repeat business. Differentiate Your Market Position: Showcase your specialized GPCR expertise to stand out from competitors and attract high-value biotech and pharma partners. Power Discovery How We Work: Your Path to GPCR Success 1 Initial Strategic Alignment We begin with a focused discussion of your current GPCR program and critical challenges, identifying precise areas for collaboration. 2 Define Actionable Objectives Together, we clarify specific, measurable goals, from target validation and assay development to CRO selection or portfolio strategy, ensuring a tailored approach. 3 Collaborative Execution & Impact I integrate directly into your discovery process to remove roadblocks, enhance execution, and generate actionable scientific data, driving confident decisions and sustained preclinical progress. Advance My Discovery My Approach: Precision Guidance for GPCR Programs I provide the focused, scientific expertise that accelerates complex GPCR discovery programs, ensuring clarity and de-risking your path from target to candidate. I integrate seamlessly with biotech, VC, and CRO teams as a trusted, objective partner. Integrated Strategic Partnership We collaborate directly with your scientific and leadership teams. This partnership prevents bottlenecks and optimizes resource allocation, ensuring every strategic decision efficiently propels your program forward and aligns with critical business objectives. Biology-First, Data-Driven Solutions Every recommendation is rooted in GPCR biology, pharmacology experience. This provides evidence-based strategies leveraging deep GPCR expertise to overcome specific scientific challenges and maximize your program's potential. Accelerated Preclinical Progression I streamline critical operational processes, from advanced assay design and CRO management to rapid go/no-go decision-making. This focused execution accelerates preclinical milestones and maximizes the efficiency and return on your R&D investment. Core Values: The Foundation of Every Successful Partnership My advisory is built on principles that ensure clarity, minimize risk, and drive enduring results in GPCR drug discovery. Scientific Integrity Every recommendation is rigorously evidence-based, not reliant on assumptions. This ensures robust, defensible decisions that de-risk your program from early discovery to regulatory milestones. Operational Discipline I instill structure and consistency across every phase of your discovery process. This approach eliminates inefficiencies and standardizes workflows, accelerating your path to a preclinical candidate. Collaborative Partnership I operate as an embedded, invested partner with your team. Your program's success is my priority, fostering a transparent, results-driven environment that maximizes collective expertise and accelerates progress. About Yamina A. Berchiche I'm Yamina A. Berchiche, and I understand the intricate challenges of GPCR drug discovery. Small missteps can derail entire programs: underperforming assays, off-track CROs, and data that fails to drive decisions. That's precisely where my expertise becomes your strategic advantage. With over two decades dedicated to GPCR pharmacology across biotech, academia, and the non-profit sector, I bring unparalleled scientific depth and operational precision to every project. My work focuses on integrating directly with your team as a strategic partner. Whether it's optimizing CRO selection, building robust internal capabilities, or translating complex data into decisive program advancements, I help you eliminate friction, align efforts, and accelerate your path to success. As the founder of Dr. GPCR, I also offer a unique, broad perspective and trusted relationships within the field. This allows me to connect you with critical insights and key collaborators, further accelerating your progress in GPCR drug discovery. Let's Talk Discovery What Partners Say Here’s what it’s like to work together — from people I’ve supported on both sides of the bench. Anne Marie Quinn, CEO Montana Molecular Before working with Yamina, we were generating high-quality data across biotech programs but often navigating evolving expectations and goals from different stakeholders. After partnering with her, communication became clearer, deliverables were better defined, and collaboration across teams ran more smoothly. She helped streamline complex projects and made the CRO–client relationship more effective and productive. Terry Kenakin, PhD UNC Chappel Hill Yamina brings scientific clarity, leadership, and precision execution to complex pharmacological programs. I’ve worked with her on several discovery programs; in fragmented programs she bought clarity and decision points that produced much better candidate progression. I am always delighted to work with Yamina as it always leads to an overall better and harmonious discovery program. Murat Tunaboylu, CEO Antiverse Before engaging Yamina, our team faced hurdles in navigating complex early discovery decisions. We had critical program choices ahead and needed clear direction. Bringing her in was a turning point. We swiftly made confident progress on a pivotal program and gained absolute clarity on our next strategic focus. Yamina was instrumental in unifying our scientific and operational teams, fostering crucial alignment and driving decisive momentum across every aspect of execution. Book Book My 30 Minutes Strategy Call Menu Home Services About News Ready to collaborate? Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution across biotech, VC, and CRO teams. Get in touch Connect LinkedIn Podcast Dr. GPCR Calendly ©2023-2025 All rights reserved by FindYooour, LLC & Dr. GPCR Corp Proudly created with Wix.com

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session IX / Technology capsule: Light on aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing monoclonal antibody drugs against GPCRs and other multi-pass transmembrane targets, such as ion channels, remains a significant challenge. Novoprotein developed a NovoiSMART technology, utilizing mRNA-based immunization, which can overcome these obstacles by producing high-quality antibodies that more accurately mimic natural protein structures. This approach contrasts with other antigen forms like peptides or DNA, which face limitations in structural integrity and immunogenicity. mRNA technology, demonstrated in the success of COVID-19 vaccines, is emerging as a promising method for antibody discovery. Several case studies of GPCR and other multi-pass transmembrane targets are presented, including GPRC5D, Claudin 6 and Napi2b. These studies show that mRNA immunization yields higher antibody titers and greater epitope diversity compared to other methods. These examples underscore the potential of NovoiSMART technology in developing highly specific antibodies for complex targets, with implications for overcoming challenges like drug resistance and tumor escape. About Gavin Zhang Gavin is a currently a director of business and operations at Novoprotein Scientific. His research experience includes phylogenetics and cancer epigenetics. Gavin Zhang on the web LinkedIn < Previous Session Next Session >

Find answers to all your questions about the Dr. GPCR Ecosystem: courses, podcasts, memberships, events, and more. Frequently asked questions University Vault Premium Pricing GPCR Masterclass YC-Biotech YC-VC YC-CRO Terrys Corner Media Partner Foundry General University Dr.GPCR Podcast What is the University Vault? An exclusive, members-only archive of expert talks from past DrGPCR events, plus comprehensive courses and career resources. Who is it for? Researchers, scientists, postdocs, graduate students, and professionals in GPCR-related fields looking to advance their careers. Is the content still relevant? Absolutely. These presentations provide foundational and advanced insights that continue to inform current research, plus we continuously add new content. How often is new content added? New sessions are uploaded after each DrGPCR Summit or Symposia, plus we regularly add new courses, news, and update career resources.

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Leaving for City Center Coming Soon < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Registration & Coffee with light breakfast < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session II AGPCR signaling pathways and trafficking Localization of putative ligands for adhesion G protein-coupled receptors in mouse tissues. Yuling Feng The ADGRF5/GPR116 receptor is a key regulator of lymphatic endothelial cell identity and function Monserrat Avila Zozaya Adhesion GPCR BAI1/ADGRB1 can block IGF1R-mediated growth signalling, increase radiosensitivity and augment survival in medulloblastoma. Erwin G. Van Meir Site Specific N-Glycosylation Of The N-Terminal Fragment Of ADGRG6 Drives Proteolytic Processing, Trafficking And Signalling Pal Kasturi Localization of putative ligands for adhesion G protein-coupled receptors in mouse tissues. Yuling Feng Abstract Only available for AGPCR 24 Workshop Attendees Authors & Affiliations "Shen,Tingzhen; Bernadyn,Tyler; Kwarcinski, Frank; Gandhi, Riya; Tall, Greg. University of Michigan." About Yuling Feng "I am currently a postdoctoral research fellow working with aGPCR pharmacology and physiology in rodents." Yuling Feng on the web LinkedIn The ADGRF5/GPR116 receptor is a key regulator of lymphatic endothelial cell identity and function Monserrat Avila Zozaya Abstract Only available for AGPCR 24 Workshop Attendees Authors & Affiliations "Serafin D. Stephen, Caron Kathleen M Department of Cell Biology and Physiology at UNC Chapel Hill 111 Mason Farm Road, MBRB, CB 7545. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA 27599" About Monserrat Avila Zozaya "My doctoral research was focused on investigating the cellular effects of missense lung cancer-mutations in the G-protein-coupled receptor Autoproteolysis-Inducing (GAIN) domain of Latrophilin 3 receptor under the mentorship of Dr. Antony Boucard. I am currently a postdoctoral researcher fellow in Dr. Kathleen Caron's laboratory at UNC. My research focuses on understanding the molecular mechanisms of adhesion GPCRs (aGPCRs) in lymphatic endothelial cells (LECs), a cellular model with unique junction arrangements where aGPCRs are mainly unexplored. " Monserrat Avila Zozaya on the web LinkedIn Caron Lab Antony Boucard Lab Dr. GPCR Adhesion GPCR BAI1/ADGRB1 can block IGF1R-mediated growth signalling, increase radiosensitivity and augment survival in medulloblastoma. Erwin G. Van Meir Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Yamamoto, Takahiro 1,2*, De Araujo Farias, Virginea 1, Zhu, Dan3; Kuranaga, Yuki1, Parag, Rashed Rezwan 1,4,, Osuka, Satoru1,5 1 Department of Neurosurgery, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. 2 Department of Neurosurgery, Kumamoto University, Kumamoto, Japan 3 Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA 4 Graduate Biomedical Sciences, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA 5 O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA " About Erwin G. Van Meir "Dr. Erwin Van Meir is a professor in the UAB Department of Neurosurgery. He was trained in molecular biology at the Universities of Fribourg and Lausanne, Switzerland where he obtained his Ph.D. in 1989. Dr. Van Meir pursued postdoctoral work at the Ludwig Institute for Cancer Research in San Diego and joined the faculty of Emory University in 1998. His research interest lies in understanding the molecular basis for human tumor development and how to use this knowledge to devise new therapeutics that will improve patient survival. Van Meir’s research examines how genetic alterations and hypoxia induce changes in cell biology that promote tumor formation with particular emphasis on adhesion GPCRs ADGRB1 and ADGRB3. Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic molecules and is currently developing novel small molecule inhibitors of the hypoxia-inducible factor pathway and the epigenetic reader MBD2 (methyl CpG binding protein 2). His research aims to translate these novel agents to testing in clinical trials with the hope to develop novel medicines for cancer treatment." Erwin G. Van Meir on the web Google Scholar Site Specific N-Glycosylation Of The N-Terminal Fragment Of ADGRG6 Drives Proteolytic Processing, Trafficking And Signalling Pal Kasturi Abstract "ADGRG6 is a member of the adhesion G-protein-coupled receptor (aGPCR) family, known to play a role in myelination, placentation, blood vessel, and inner ear development. Like many other aGPCRs, ADGRG6 undergoes autoproteolysis at the GPCR-autoproteolysis site (GPS) enclosed within the larger GAIN domain to generate the N-terminal (NTF) and C-terminal fragments (CTF). These cleaved fragments join to form the heteromeric ADGRG6 receptor complex. ADGRG6 NTF has multiple extracellular domains like CUB, PTX, SEA, hormone binding domain, and the GAIN domain, which regulate G-protein signaling by binding to extracellular matrix proteins and mechanotransduction. The short stachel sequence at the extreme N-terminal end of the CTF functions as a tethered agonist to activate cAMP signaling. GPCR signaling and trafficking can be regulated by several different post-translational modifications (PTM). Stehlik et al. have reported that ADGRG6 expressed in lipopolysaccharide stimulated human umbilical vein endothelial cells is N-glycosylated. However, it is unclear which domains of ADGRG6 are N-glycosylated and how this might affect the overall molecular pharmacology of the receptor. Furthermore, are there spatial roles of N-glycosylation in ADGRG6 processing, trafficking, signalling and in-vivo functions? To address these gaps in knowledge, we used biochemical and cell-biological approaches using cell-lines overexpressing wild-type and N-glycosylation mutants of ADGRG6. We observed that N-glycosylation specifically takes place in the NTF and not the CTF of ADGRG6. Our results demonstrate that specific N-glycan residues in different domains of the extracellular NTF of ADGRG6 have distinct roles in ADGRG6 autoproteolysis, furin cleavage, membrane trafficking, and G-protein signalling. In the future, we plan to decipher the roles of N-glycosylation of ADGRG6 in organogenesis and tissue development using zebrafish models." Authors & Affiliations "Anandhu Jayaraman: Department of Biology, Ashoka University Prabakaran Annadurai: Department of Biology, Ashoka University. Currently: University of Leipzig Mansi Tiwari: Department of Biology, Ashoka University. Currently: University of Aberdeen Priyadatha Sajan: Department of Biology, Ashoka University, Currently: University of Groningen Nayonika Chatterjee: Department of Biology, Ashoka University Prateek Sibal: Department of Biology, Ashoka University" About Pal Kasturi "I received my bachelor’s degree in Physiology from Presidency College, University of Calcutta and went on to complete my masters from Madurai Kamaraj University. During my PhD training, I worked in the laboratory of Dr. Kathryn Defea at the University of California, Riverside. For my PhD thesis, I worked on non-canonical, scaffold driven signaling by protease activated receptor-2 (PAR2). I joined University of Texas Southwestern Medical Center, for my postdoctoral training. Here, I worked on the regulation of the Sonic Hedgehog pathway by GPCRs which localized to the primary cilia. I then joined the laboratory of Dr. Velia Fowler, at the Scripps Research Institute, as a Judith Graham Poole postdoctoral fellow to work on the role of cytoskeletal proteins in megakaryocyte to platelet differentiation. I joined the Department of Biology at Ashoka University in 2020 as an assistant professor." Pal Kasturi on the web Ashoka University < Previous Session Next Session >

Join the Dr. GPCR Affiliate Program and earn commissions by helping connect the global GPCR community. Share our ecosystem, courses, and events to advance drug discovery together. Dr. GPCR Affiliate Program Earn by Empowering the GPCR Ecosystem Help us connect scientists, founders, and innovators while earning commissions for every member, partner, or course you bring into the Dr. GPCR community. Become our Brand Ambassador Our vision is to build the best platform for the GPCR community and help you the scientists and business owners to share their experiences with others, get help, and find the perfect tools, colleagues, build their strategy and advance our field. As an ambassador, with the Affiliate Program, you'll earn a commission whenever your referral link is used and a qualified purchase has been made by your friends, colleagues, or followers who are also part of the GPCR field. Become our Brand Ambassador About Dr. GPCR Ecosystem We aspire to provide opportunities to connect, grow, and thrive together as a dynamic group. The goal is to better understand and exploit the druggability of GPCRs, together. The Dr. GPCR Ecosystem members have the opportunity to solve problems, find answers to their questions, identify the perfect service provider, and, most importantly, boost their GPCR project with just a few clicks. The Ecosystem is designed for all GPCR professionals to have an affordable and highly effective way to showcase their knowledge, connect, and advance the field, together. About the Dr. GPCR brand ambassador affiliate program Who can be a Dr. GPCR ambassador? Scientists and trainees with a strong GPCR background who like and want to create content by writing articles about their favorite GPCR topics and sharing these on social media platforms such as LinkedIn and other options listed at the end of this page. Who is eligible for the Dr. GPCR affiliate program? A GPCR background is mandatory independent of your current position and industry. You also must be an individual Dr. GPCR Ecosystem membership holder. For full details on eligibility, please read our Affiliate Policy . How do I apply for the affiliate program? To become an affiliate, you must create an account here . How does the Dr. GPCR affiliate program work? After becoming a member of the affiliate program, you'll get your personalized link where you can send your potential clients. After every qualified sale, you will earn a commission of $50. How does the commission work? Each qualifying sale earns a commission (excluding sale cancellations). Does it cost me anything to become an affiliate? The program is free to join; there are no monthly charges and no minimum sales requirements. However, the number of ambassador members is limited. Dr. GPCR reserves the right to remove the least active members from the program. Can I invite someone to participate? Yes! You can invite anyone to participate, and we welcome anyone if they are qualified. Do I need to sign a contract? There's no contract to sign when joining our program. You will be required to agree to our Terms and Conditions and our Affiliates Policy when you sign up on Ecosystem.DrGPCR.com. You can leave the program at any time by contacting us. Dr. GPCR may also remove affiliates from the program at any time. Is there an exclusivity agreement when joining? There's no exclusivity agreement. You can take part in other affiliate programs as well as be part of ours. Are affiliates outside of the U.S. eligible for the Affiliate Program? Yes, you may join the affiliate program as long as you have a verified PayPal account. What type of channels, tools, and techniques can I use to promote Dr. GPCR Ecosystem? OK to use: - Writing, blogging, guest blogging, - Podcast, video, vlog - Social media sharing, - YouTube & TikTok channels, - Business Page and website, - Informational and fan sharing, - Presentations and meetups. Not OK to use: Advertising Spam Anything misleading or annoying Social media bios Paying or offering intensives for the use of your link How do I track my earning? We use a third-party provider, GoAffPro.com , where you'll create your own account and through your dashboard, you can track all your activities. When will I receive my affiliate commissions? Affiliate payments are processed and sent directly to your PayPal in 7 to 30 days. We could hold payments up to 30 days to allow for processing, chargebacks, etc. Good Faith We introduce programs such as the Dr. GPCR Ambassador, in good faith and expect the same good faith in return. Please note that we may withhold awards where we believe customers are acting in bad faith or otherwise acting contrary to the intent of this program. To be clear, commercializing, advertising, publishing, mass distributing, selling, or paying for the use of referral links is not appropriate, and we will not honor such links. We cannot cover every nefarious scenario, nor will we attempt to, but we do promise to be fair and reasonable. Closure We are so excited about the Dr. GPCR Ambassador program. It will be a remarkable journey and fun to build together the "next-generation" platform for the B2B industry. With your help, we can create a world where the living experience is joyful and worry-free. Are you ready? Sign up , explore, and connect with us. Become our Brand Ambassador

Fast-track your biotech investments with VC Insights. Access expert guidance, vetted CROs, and data-driven strategies to invest smarter and move faster in GPCR drug discovery. Home About Services News Get in Touch Welcome VC Insights Fast Track Your Next Biotech Bet Get decision-grade data, vetted CROs, and expert guidance—so you move fast and invest smarter. I help you avoid costly delays, choose the right experiments, and unlock clear timelines that drive confident investment. Fast Track My Discovery The wrong CRO—or wrong experiments—can burn months and millions You're not here to fund academic detours. You're backing science that needs to move fast. But too often I hear: “We thought the experiments made sense—until the data didn’t help us decide.” “The CRO promised timelines they couldn’t hit.” “The team’s updates sound polished, but we can’t tell if they’re on track.” If you’ve said any of those, you’re not alone. That's where I come in : to pressure-test the science, align the strategy, and make sure every experiment earns its place. How I Drive Value Prioritize the Right Experiments Avoid noise. I help identify the experiments that truly matter—aligned to your milestones and inflection points. Translate project strategy into clear decision-driving assays Eliminate “nice to have” tests that stall timelines without payoff Match experiments to the specific phase and risk tolerance of the asset De-risk Your CRO Strategy I evaluate, select, and manage CROs that are fit-for-purpose—saving you time, cost, and rework. Audit and compare CRO options based on speed, quality, and fit Clarify deliverables and oversight to prevent rework and misfires Serve as a scientific bridge between VC, team, and CRO Move With Clarity and Speed Every week counts. I bring structure, decision frameworks, and momentum so your team stays on track. Build plans aligned to go/no-go moments, not busywork Drive regular check-ins that produce clear, actionable updates Anticipate delays and adapt quickly with contingency-ready paths " Yamina brings scientific clarity, leadership, and precision execution to complex pharmacological programs. I’ve worked with her on several discovery programs; in fragmented programs, she brought clarity and decision points that produced much better candidate progression. I am always delighted to work with Yamina as it always leads to an overall better and harmonious discovery program." - Terry Kenakin, PhD - UNC Chappel Hill Frequently Asked Questions 01 How quickly can you get started? I begin with a 30-minute call to understand your goals. From there, I deliver a roadmap or assessment within 1–2 weeks. 02 Do you only work post-investment? No—many VCs engage me before investing to assess targets, pressure-test science, or evaluate CRO readiness. 03 What if we already have a team? Perfect. I plug in as a strategic partner—complementing internal talent to bring execution clarity and scientific rigor. Let's turn complexity into confidence—with the data you need to move forward. Chat about My Discovery Send me a message First name* Last name Company name* Email* How Can I Help?* Send Message or Book My Call Menu Home Services About Ready to collaborate? Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution across biotech, VC, and CRO teams. Get in touch Connect LinkedIn Podcast Dr. GPCR Calendly ©2023-2025 All rights reserved by FindYooour, LLC & Dr. GPCR Corp Proudly created with Wix.com

Support the Adhesion GPCR Workshop 2024 with a donation. Help advance GPCR research, enable education, and connect the scientific community. DONATIONS Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Our Sponsors

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda State of the Art Talk Adhesion GPCR in Mechanobiology Abstract Only Available for AGPCR24 Attendees About Tobias Langenhan "1997-2004: Medical school and Dr. med. Neuroanatomy (Würzburg, Germany); 2004-2005: M.Sc . Neuroscience (Oxford, UK); 2005-2009: D.Phil. Neuroscience (Oxford, UK); 2009-2016: Group leader, Institute of Neurophysiology (Würzburg, Germany); 2016: Heisenberg professorship (Würzburg, Germany); 2016-to date: Professor and Chair in Biochemistry (Leipzig, Germany)" Tobias Langenhan on the web Langenhan Lab LinkedIn < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Welcoming Remarks < Previous Session Next Session >

Join the GPCR Retreat: Exploring the Frontiers of GPCR Biology! Engage with leading minds from academia and industry, fostering discussions on cell communication and novel concepts. Embrace diversity in a limited-capacity event fostering mentor-trainee interactions. Retreat 2023 About Program Registration Logo Contest Committee Sponsors 22nd GPCR Retreat Fairmont Le Château Montebello, Québec, Canada November 2-4, 2023 We are pleased to welcome you at Le Château Montebello , the 22nd Annual Great Lakes G Protein-Coupled Receptor Retreat held jointly with the Club des Récepteurs à Sept Domaines Transmembranaires du Québec. The meeting will be held on Nov. 2-4, 2023 at the Chateau Montebello, Québec. The Chateau Montebello is an exceptional venue, and is located 1 hr from Ottawa, or 1.5 hr from Montreal in the beautiful Laurentian Mountains of Canada. The fall colors of the leaves are spectacular, and the weekend of science is an intense and interactive experience, and a great training environment for our students and post-doctoral fellows. The meeting is launched on Thursday with two Trainee Symposia and the Plenary Lecture, followed by 6 symposia on Friday and Saturday and the closing Keynote Lecture. The deadline for registration is September 21, 2023. For the 22nd edition, the Organizing Committee has again lived up to the expectations by putting together an outstanding program with a special thought for Marc Caron (1946-2022) to commemorate his great contributions to the GPCR and Neurosciences fields. Dr. Kathleen Caron of the University of North Carolina at Chapel Hill, unquestionably one of the pioneers involved in deciphering how receptor activity-modifying proteins or RAMPs regulate GPCR function, is confirmed as Plenary Speaker of the inaugural Marc G. Caron keynote lecture on November 2nd. Additionally, there will be a Marc G. Caron Honorary Symposium by Caron Lab alumni to honor his memory. We have also confirmed Dr. Arthur Christopoulos of Monash University in Australia, one of the pioneers in the medicinal chemistry, computational and mathematical modelling of GPCRs, as Plenary Speaker of the Hyman B. Niznik keynote lecture , which will close the conference. The program will include also world-class and diverse GPCR scientists working in the arenas of structure and signaling, neuroscience, cancer, translational and model systems. As in previous editions, trainees are more than welcome to this unique meeting. Indeed, for the Montebello 2023 edition, we have organized two trainee symposiums to acknowledge formally the participation of our graduate students and post-doctoral fellows. Additionally, each symposium of the GPCR Retreat 2023 will include one trainee short talk selected from abstracts. Trainees of diversity groups are strongly encouraged to register to the meeting and submit an abstract for consideration for the trainee symposia and selected trainee short talks. Your participation has already made this unique event a success. We are thrilled by the overwhelming interest in this event by the GPCR research community. We trust that the collegial and intimate atmosphere provided by Le Château Montebello will be suited for an environment where graduate students, postdoctoral fellows and principal investigators can have stimulating discussions and debates on GPCR research presented at this meeting. We would like to thank all our Sponsors for their ongoing generous support of the meeting. Without their support, this meeting will not be possible. If you have any suggestions or comments for either this Retreat or future meetings, we look forward to receiving your feedback. Finally, Bienvenue and we hope you will enjoy your stay in Montebello and find the Retreat stimulating and satisfying. Sincerely , The Organizing Committee Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Unveiling Non-Canonical Functions for Gαq Signaling Pathways Date & Time Friday, November 3rd / 11:55 AM About Catalina Ribas " Dr. Catalina Ribas, is currently an Associate Professor at the University Autonomous of Madrid (UAM) and she has been Academic Secretary of Molecular Biology Department for several years. The research group led by Dr. Catalina Ribas, located in the Centro de Biología Molecular “Severo Ochoa” (UAM/CSIC) and belongs also to the Health Research Institute La Princesa, has extensive experience in the field of GPCR. Dr. Catalina Ribas made a postdoctoral stay in the laboratory of Dr. SM. Lanier in the MUSC (USA). During this period and her doctoral thesis, she has deepened the regulatory mechanisms of GPCR signaling. In her postdoctoral period, she has participated in the identification and characterization of proteins that act at the level of G proteins and which are part of a multimolecular signaling complex (AGS, de “Activators of G-protein signaling). In Spain, Dr. Ribas continued working on the regulation of GPCR. The group of Dr. Ribas has characterized the existence of a new signaling pathway with a relevant role in cardiac hypertrophy led by a new Gαq interactome. Recently, Dr. Ribas' group has described a new interaction region in a cellular protein that has turned out to be very relevant in the control of the cellular process known as autophagy. These results have been published in the journal Nature Communications (12 (1):4540, 2021) with the title "Gαq controls autophagy via modulation of the mTORC1 signaling hub". Furthermore, Dr. Ribas has also described a new protective role of G protein-coupled receptor kinase 2 (GRK2), a known regulator of Gq-GPCR signaling in HNSCC tumor progression (International Journal of Cancer, 2020). " Catalina Ribas on the web Severo Ochoa Molecular Biology Center X (Twitter) Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Home → Flash News → What’s one key piece of advice from Ian Chronis in Ep.164 of the Dr.GPCR Podcast?Listen to other scientists’ research—it’s a great way to stay motivated and inspired 🚀 Don’t miss this insightful conversation on GPCRs, pharmacology, and scientific discovery! ✅ https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast #Pharmacology #CancerResearch Published on April 24, 2025 Category Dr. GPCR Podcast What’s one key piece of advice from Ian Chronis in Ep.164 of the Dr.GPCR Podcast?Listen to other scientists’ research—it’s a great way to stay motivated and inspired 🚀 Don’t miss this insightful conversation on GPCRs, pharmacology, and scientific discovery! ✅ https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast #Pharmacology #CancerResearch Previous Next Recent Articles

Home → Flash News → 🎧 "You will always feel like you know nothing— and that’s completely fine." In Ep.162 of the Dr.GPCR Podcast, Dr. Gabriele Kockelkoren shares: 🔬 How GPCR spatial organization shapes signaling and drug responses 🌍 His interdisciplinary journey from physics to pharmacology 💡 Why embracing the unknown is key to scientific breakthroughs A must-listen for biophysicists, pharmacologists, and drug hunters pushing the boundaries of discovery! 🎙️ Tune in now:Ep 162 with Dr. Gabriele Kockelkoren #DrGPCR #GPCR #Biophysics #Pharmacology #DrugDiscovery #SciencePodcast Published on March 25, 2025 Category Dr. GPCR Podcast 🎧 "You will always feel like you know nothing— and that’s completely fine." In Ep.162 of the Dr.GPCR Podcast , Dr. Gabriele Kockelkoren shares:🔬 How GPCR spatial organization shapes signaling and drug responses🌍 His interdisciplinary journey from physics to pharmacology💡 Why embracing the unknown is key to scientific breakthroughs A must-listen for biophysicists, pharmacologists, and drug hunters pushing the boundaries of discovery! 🎙️ Tune in now: Ep 162 with Dr. Gabriele Kockelkoren #DrGPCR #GPCR #Biophysics #Pharmacology #DrugDiscovery #SciencePodcast Previous Next Recent Articles

Explore this week's edition of Weekly News, featuring expert insights on target engagement, a practical framework for irreversible drugs by Terry, and Dr. Jens Carlsson's take on predictive modeling. Gain valuable strategies to advance your covalent or tight-binding candidates and enhance your experimentation process. Read more for a premium sneak peek! Home → Flash News → Weekly News October 23 Dr. GPCR Weekly News - Oct 23 - The Power and Peril of Irreversible Drugs Published on October 23, 2025 Category GPCR Weekly News This week’s Weekly News breaks down how to control target engagement—so duration, penetration, and PK/PD separation serve your program, not sink it. Premium sneak peek inside. 🔹 Terry’s Corner: A practical framework for irreversible drugs—defining “irreversible” in real systems, anticipating PK/PD decoupling, and using k_inact/K_I when Ki falls short. 🔹 Podcast Spotlight: Dr. Jens Carlsson on predictive modeling—where structure-based design and MD guide experiments (and where AlphaFold still needs a chaperone). If you’re advancing covalent or tight-binding candidates—or building models meant to predict, not narrate —this edition is built to shorten cycles and reduce surprises. Read the full Weekly News ➤ https://bit.ly/3KVlL4m If it helps your team, share it forward. #DrGPCR #GPCR Previous Next Recent Articles

Your complete guide to AGPCR24. Inside, you’ll find the schedule, speaker bios, venue map, travel tips, and essential information to make the most of your workshop experience. OFFICIAL BOOKLET Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF You can also download the booklet by scanning this QR code

Home → Flash News → A newly engineered biosensor reveals DNAJC13 as a key player in GPCR trafficking, shedding light on its role in DOR downregulation and endosomal regulation. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/an-engineered-trafficking-biosensor-reveals-a-role-for-dnajc13-in-dor-downregulation #gpcr #drgpcr Published on March 24, 2025 Category GPCR Weekly News A newly engineered biosensor reveals DNAJC13 as a key player in GPCR trafficking, shedding light on its role in DOR downregulation and endosomal regulation. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/an-engineered-trafficking-biosensor-reveals-a-role-for-dnajc13-in-dor-downregulation #gpcr #drgpcr Previous Next Recent Articles

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session VII Physiological and pathological roles of AGPCRs in the nervous system Uncovering the signaling pathway of the ADGRA homolog Remoulade in Drosophila Beatriz Blanco Redondo The Adhesion GPCR Latrophilin Interacts With The Notch Pathway To Control Germ Cell Proliferation Willem Berend Post Uncovering the signaling pathway of the ADGRA homolog Remoulade in Drosophila Beatriz Blanco Redondo Abstract "The Drosophila genome contains five loci encoding adhesion G-protein coupled receptors (aGPCRs). Phylogenetic analysis revealed that the remoulade (remo) gene is a homologue of the vertebrate aGPCR ADGRA family, sharing the same overall receptor domain structure. In vivo expression profiling has shown Remo expression in the central (CNS) and peripheral nervous systems (PNS) of third-instar larvae (L3) and adults. In L3 PNS specimen Remo is expressed in a subset of neurons expressing the DEG/ENaC channel pickpocket (PPK), which is involved in transduction of sensory information like nociception. remoKO larvae and animals, in which remo was knocked down in ppk-neurons through RNA interference, show a higher nocifensive response compared to wildtype remorescue controls indicating that remo is required in PPK-neurons for this behaviour. Furthermore, with the aim to analyse the biochemical properties of Remo, we performed immunoprecipitation analysis. We found that the receptor is cleaved despite the lack of a consensus GPS sequence. Hence, Remo is proteolytically processed, either by the GAIN domain or an alternative protease that cleaved Remo near the GPS. We also aimed at identifying the signaling pathway that Remo is involved in. The mammalian Remo homolog ADGRA2/Gpr124 cooperates with other GPCRs of the Frizzled family, and the transmembrane proteins RECK and Lrp5/6. Collectively these proteins form a cell surface complex that acts as a recognition platform for Wnt ligands. Knowledge of the structural dynamics of this complex is limited and pharmacological and in vivo systems that would allow its characterization are scarce. Remo may serve a role in this peculiar signaling pathway and require further analysis." Authors & Affiliations "Auger, Genevieve Marie1, Bigl, Marina1, America, Michelle2, Vanhollebeke Benoit2, Langenhan Tobias1 1Rudolf Schönheimer Institute of Biochemistry, Division of General Biochemistry, Medical Faculty, Leipzig University, Johannisallee 30, 04103 Leipzig, Germany 2Laboratory of Neurovascular Signaling, Department of Molecular Biology, ULB Neuroscience Institute, Université libre de Bruxelles (ULB), Gosselies B-6041, Belgium" About Beatriz Blanco Redondo "I studied Biomedicine at the University of Barcelona. After my bachelors, I moved to Germany where I obtained my Master’s of Science and PhD degree in Dr. Buchner’s group at the University of Wuerzburg. Shortly after receiving my PhD, I joined Dr. Neil Shneider’s group as a postdoctoral research scientist at Columbia University, New York, where I studied the mechanisms of motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS). In 2017, I joined the group of Prof. Langenhan where I am studying and characterizing newly generated adhesion GPCR receptors in Drosophila as a model organism for future pharmacological applications." Beatriz Blanco Redondo on the web Blanco-Redondo Lab LinkedIn Google Scholar X (Twitter) The Adhesion GPCR Latrophilin Interacts With The Notch Pathway To Control Germ Cell Proliferation Willem Berend Post Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Groß Victoria Elisabeth 1, Matúš Daniel 2,3, Kaiser Anette 4, Ließmann Fabian 5, Meiler Jens 5, Schöneberg Torsten 2,6, Prömel Simone 1 1 Institute of Cell Biology, Department of Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany 2 Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, Leipzig University, Leipzig, Germany 3 Department of Molecular and Cellular Physiology, Stanford University, Stanford CA, USA 4 Department of Anaesthesiology and Intensive Care, Medical Faculty, Leipzig University, Leipzig, Germany 5 Institute for Drug Discovery, Faculty of Medicine, Leipzig University 6 School of Medicine, University of Global Health Equity, Kigali, Rwanda" About Willem Berend Post "Willem Berend Post is a PhD student in Cell Biology at Heinrich Heine University in Düsseldorf, Germany. His research focuses on the relevance of aGPCRs in physiology and signaling using both in vitro and in vivo approaches." Willem Berend Post on the web Cell Biology LinkedIn < Previous Session Next Session >

Home → Flash News → The GPCR world is waiting to see YOU. Update your profile today and be part of the biggest GPCR community in the world 🌏 ✳️Visit https://www.ecosystem.drgpcr.com/account/my-account and share your updated information 😉 #gpcr #drgpcr Published on February 11, 2025 Category Dr. GPCR Profiles The GPCR world is waiting to see YOU. Update your profile today and be part of the biggest GPCR community in the world 🌏 ✳️ Visit https://www.ecosystem.drgpcr.com/account/my-account and share your updated information 😉 #gpcr #drgpcr Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Home → Flash News → The registration deadline for the 1-day workshop “The Practical Assessment of Signaling Bias” is TOMORROW! ⏰ Save your spot in a class with the Master of Pharmacology Dr. Terry Kenakin, and get 25% off with your Premium Membership. An advanced lecture, hands-on exercises, one private call with the professor, and more! ✳️Click here https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on February 17, 2025 Category Dr. GPCR Courses The registration deadline for the 1-day workshop “The Practical Assessment of Signaling Bias” is TOMORROW! ⏰ Save your spot in a class with the Master of Pharmacology Dr. Terry Kenakin, and get 25% off with your Premium Membership. An advanced lecture, hands-on exercises, one private call with the professor, and more! ✳️Click here https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Previous Next Recent Articles

Home → Flash News → How do GRK-specific phosphorylation barcodes influence β-arrestin binding to GPCRs? New cryo-EM structures from Chen et al. (Nature, 2025) reveal that β-arrestin1 and β-arrestin2 form distinct complexes with ACKR3 depending on whether it's phosphorylated by GRK2 or GRK5, shaping arrestin conformation, complex stability, and engagement mode. Surprisingly, arrestin’s finger loop didn’t dive into the receptor core. Instead, it latched onto the micelle surface, breaking canonical expectations. Also, β-arrestin2 lacks a membrane anchor, making it more dynamic — a potential clue to its functional specialization. These findings underscore how barcode location + arrestin isoform = unique signaling outcomes. open book Read the full study: Inside Out: Mapping GPCRs from Membrane Codes to Market Moves #GPCRs #Arrestin #ACKR3 #GRKs #CryoEM #StructuralBiology #SignalingBias #Phosphorylation #DrGPCR Published on June 9, 2025 Category GPCR Weekly News How do GRK-specific phosphorylation barcodes influence β-arrestin binding to GPCRs? New cryo-EM structures from Chen et al. (Nature, 2025) reveal that β-arrestin1 and β-arrestin2 form distinct complexes with ACKR3 depending on whether it's phosphorylated by GRK2 or GRK5, shaping arrestin conformation, complex stability, and engagement mode. Surprisingly, arrestin’s finger loop didn’t dive into the receptor core. Instead, it latched onto the micelle surface, breaking canonical expectations. Also, β-arrestin2 lacks a membrane anchor, making it more dynamic — a potential clue to its functional specialization. These findings underscore how barcode location + arrestin isoform = unique signaling outcomes. Read the full study: Inside Out: Mapping GPCRs from Membrane Codes to Market Moves #GPCRs #Arrestin #ACKR3 #GRKs #CryoEM #StructuralBiology #SignalingBias #Phosphorylation #DrGPCR Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Home → Flash News → A new study from the Hudson Lab at the University of Glasgow shows that the FFA receptor antagonist AH7614 is actually an inverse agonist - suppressing fat cell formation, boosting lipolysis and reducing glucose uptake. Explore how targeting FFA4 could help fight metabolic disorders. Catch up with the latest research conducted in the Hudson lab in Ep. 161 of the Dr. GPCR Podcast. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/inverse-agonism-of-the-ffa4-free-fatty-acid-receptor-controls-both-adipogenesis-and-mature-adipocyte-function #GPCR #drGPCR #FFA4 #metabolism #adipocytes” Published on April 7, 2025 Category GPCR Weekly News A new study from the Hudson Lab at the University of Glasgow shows that the FFA receptor antagonist AH7614 is actually an inverse agonist - suppressing fat cell formation, boosting lipolysis and reducing glucose uptake. Explore how targeting FFA4 could help fight metabolic disorders. Catch up with the latest research conducted in the Hudson lab in Ep. 161 of the Dr. GPCR Podcast. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https:// www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/inverse-agonism-of-the-ffa4-free-fatty-acid-receptor-controls-both-adipogenesis-and-mature-adipocyte-function #GPCR #drGPCR #FFA4 #metabolism #adipocytes Previous Next Recent Articles

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule "Have a nice weekend, and I'll see you tomorrow!": RAMP-interacting GPCR Pathways Date & Time Thursday, November 2nd / 4:30 PM Keynote Talk Abstract Coming Soon About Kathleen Caron "Kathleen M. Caron, Ph.D. is the Frederik L. Eldridge Distinguished Professor and Chair of the Department of Cell Biology & Physiology at The University of North Carolina at Chapel Hill—a large, interdisciplinary basic science department consistently ranked in the Top 5 in the Nation in NIH funding. Dr. Caron received a BS in Biology and BA in Philosophy at Emory University and a PhD at Duke University while training with Dr. Keith Parker to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models. She pursued postdoctoral training with Nobel Laureate Dr. Oliver Smithies at UNC-CH, where she was the first to discover the essential role of adrenomedullin peptide for embryonic survival. With a special emphasis on G protein coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease, preeclampsia and sex-dependent cardiovascular disease. Dr. Caron has received numerous awards including a Burroughs Wellcome Fund Career Award in the Biomedical Sciences, an Established Investigator Award and an Innovator Award from the American Heart Association, a Jefferson Pilot Award in Biomedical Sciences and a UNC-CH Mentoring Award. She currently serves as Associate Editor of Physiological Reviews; the #1 ranked journal in Physiology (IF 46.5). Dr. Caron is also past Associate Editor at JCI and served as the inaugural Associate Editor at ACS-Pharmacology and Translational Science. Dr. Caron currently holds multiple scientific advisory roles in academia, industry and the National Institutes of Health." Kathleen Caron on the web UNC-Chapel Hill Department of Cell Biology and Physiology UNC Lineberger Comprehensive Cancer Center Twitter Google Scholar ORCID ResearchGate Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Michelle describes how reading those early papers on lipid-rich domains and GPCR–G protein compartmentalization reframed her view of receptor pharmacology. Home → Flash News → where signaling happens inside a cell Why does it matter where signaling happens inside a cell? Published on November 13, 2025 Category Dr.GPCR Podcast Why does it matter where signaling happens inside a cell? This moment cuts straight to the heart of how many of us fell in love with GPCR biology — that realization that signaling isn’t random. It’s structured, organized, and spatially constrained. Michelle describes how reading those early papers on lipid-rich domains and GPCR–G protein compartmentalization reframed her view of receptor pharmacology. This shift — from thinking about “pathways” to understanding localized signaling architecture — is what drove her to build a research career around spatial control of GPCR signaling. This isn’t just academic. The way signals are organized defines specificity, drug response, and potential for targeted therapies. If you work with GPCRs, this perspective changes how you design experiments and interpret data. 🎧 Watch this insight — or listen to the full conversation with Michelle.🔗 Full episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling ✨ Join Premium: https://www.ecosystem.drgpcr.com/gpcr-university-pricing #GPCR #DrGPCR Previous Next Recent Articles

Home → Flash News → Ben Clements reveals a 10x improvement in efficacy using GPCR-targeted PAMs, in Ep.166 of the Dr.GPCR Podcast,. The catch? It’s all about understanding the system, not replacing it. From neuromas to novel modulators, this episode is full of breakthroughs that matter for patients. 📲 Watch now: Ep 166 with Dr. Ben Clements #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Published on May 22, 2025 Category Dr. GPCR Podcast Ben Clements reveals a 10x improvement in efficacy using GPCR-targeted PAMs, in Ep.166 of the Dr.GPCR Podcast,. The catch? It’s all about understanding the system, not replacing it. From neuromas to novel modulators, this episode is full of breakthroughs that matter for patients. 📲 Watch now: Ep 166 with Dr. Ben Clements #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Home → Flash News → Did you know that GPR20, a potential therapeutic target to treat gastrointestinal stromal tumours, performs high constitutive activity when coupling with Gi? Check out this paper to see how molecular dynamics simulation can be used to explore its constitutive activation mechanism. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/exploring-the-constitutive-activation-mechanism-of-the-class-a-orphan-gpr20 #gpcr #drgpcr Published on February 13, 2025 Category GPCR Weekly News Did you know that GPR20, a potential therapeutic target to treat gastrointestinal stromal tumours, performs high constitutive activity when coupling with Gi? Check out this paper to see how molecular dynamics simulation can be used to explore its constitutive activation mechanism. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/exploring-the-constitutive-activation-mechanism-of-the-class-a-orphan-gpr20 #gpcr #drgpcr Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Dr. Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights. Home → Flash News → How sensitive can a GPCR really be How sensitive can a GPCR really be? Published on November 9, 2025 Category Dr. GPCR Podcast Think femtomolar. That’s the scale we’re talking about. This week on the Dr. GPCR Podcast , we sit down with Michelle Halls , leader of the Spatial Organisation of Signalling lab at Monash University. Her team is redefining how we understand GPCR signaling — not just at the cell surface, but in space, time, and disease context. In this episode, you’ll learn: How GPCR pre-assembly enables femto-level signal detection. Why receptor location matters as much as receptor type. How disease can hijack signaling organization — and what that means for drug discovery. Michelle’s work bridges elegant mechanistic biology with translational impact — giving us new ways to think about receptor pharmacology, biased agonism, and therapeutic precision. 🔗 Listen here → https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling 🎓 Explore Dr. GPCR Premium → https://www.ecosystem.drgpcr.com/gpcr-university #GPCR #DrGPCR #pharmacology #drugdiscovery #receptors #biotech #signaltransduction Previous Next Recent Articles

Home → Flash News → ep 169 with sokhom pin some 1 Published on July 8, 2025 Category Dr. GPCR Podcast Redefine what a PhD path can look like. Sokhom S. Pin didn’t quit his job, pause his career, or sacrifice family time. He built a PhD program inside BMS—while working full-time and raising three kids. Industry-based research. Employer-funded. Custom-built for impact. 🎧 Ep. 169 is available now: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin #GPCRtraining #GPCRscientistnetwork #DrGPCR #nontraditionalPhD #GPCR #DrGPCR Previous Next Recent Articles